Retatrutide In the first phase 3 trial (TRIUMPH-4), participants lost an average of 28.7% of their body weight at 68 weeks on the highest dose (12mg), with the 9mg dose showing 26.4% weight loss
The hypothalamus with its key regions, including ARC, LHA and closely related PVN, serving as the feeding or hunger center, VMN acting as the satiety center and NTS conveying the peripheral signals, particularly from the gut to the feeding centers, are implicated in appetitive behavior
BCBS of Vermont no longer covers any GLP-1 receptor agonists FDA-approved for weight loss as of January 1, 2026
Side effects comparison Both medications share similar gastrointestinal side effects, including nausea, vomiting, diarrhoea and constipation